Skip to main content
Premium Trial:

Request an Annual Quote

Lab 7 Systems' Clinical Annotation Manager Module

Lab7 Systems has added a new module to its enterprise platform (Lab7 ESP) for managing next generation sequencing data and workflows. The new Clinical Annotation Manager module is a data management and visualization tool that ties together third-party variant annotation databases with in-house annotations and allows clinicians to quickly build ACMG-style reports from their VCF files.

Lab7 also announced this week that it is launching a Clinical Sequencing Acceleration program that will offer small pathology labs that are just starting to integrate sequencing into their offerings an opportunity to test Lab7 ESP. Pathologists who participate in the program will have full access to the Lab7 ESP under preferential licensing terms for three years. The company is currently seeking a maximum of five labs to participate in the program. The company has also launched the Academic Sequencing Acceleration Program, an open-ended program that gives academic core labs an unlimited license to the Lab7 ESP at a fraction of the cost of the full commercial license.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.